Time to mortality (overall survival) · people with liver metastases
It is very uncertain whether microwave coagulation changes time to mortality (overall survival) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse events or complications · people with liver metastases
It is very uncertain whether microwave coagulation changes any adverse events or complications compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Disease-free survival · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse events or complications · people with liver metastases
1 finding from 1 review
Disease-free survival · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with liver metastases
1 finding from 1 review
Time to mortality (overall survival) · people with liver metastases
It is very uncertain whether microwave coagulation changes time to mortality (overall survival) compared with conventional surgery (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower alemtuzumab No direct evidence (high certainty).
1 finding from 1 review
RR 0.57 [0.47, 0.68]
Studies not reported
High
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower cladribine (Direct evidence; 1 RCT; 1326 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower fingolimod (Direct evidence; 2 RCTs; 2355 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) (moderate certainty).
1 finding from 1 review
RR 0.84 [0.76, 0.93]
3 participants
Moderate
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 192 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower immunoglobulins (Direct evidence; 2 RCTs; 192 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 1.21 [0.66, 2.19]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629… (moderate certainty).
1 finding from 1 review
RR 0.84 [0.78, 0.91]
1 study · 3 participants
Moderate